Residual reversibility in COPD subjects treated by long acting bronchodilatators Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018
Effects of long acting β2-agonist, sustained-release theophylline and their combination on exercise parameters in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 287s Year: 2002
Determinants of long acting bronchodilator adherence in UK COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Respiratory muscle strength after inhaled short acting beta-agonist administration in stable COPD patients Source: Annual Congress 2012 - Mechanics, muscles and movement: aspects of airway mechanics, repiratory muscle assessment and field exercise tests Year: 2012
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Characteristics of patients newly prescribed a long acting bronchodilator in the US Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016
Which lung function variables are the most sensitive to a short bronchodilator in COPD patients? Source: Annual Congress 2008 - Quality spirometry: the only spirometry! Year: 2008
Continuous indacaterol treatment improves autonomic cardiac regulation in COPD patients Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Effects of long-acting inhaled β-adrenergic and anticholinergic drugs on respiratory function and arterial blood gases in patients with COPD Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
The effects of ELTGOL on muciciliary clearance in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 731s Year: 2006
Effects of tiotropium on neurohumoral activation during exercise in stable COPD patients Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD Source: Eur Respir J 2016; 47: 651-654 Year: 2016
Acute and chronic effects of inhaled bronchodilators in patients with 'irreversible' COPD at rest and during exercise Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015
Effects of steroid treatment on hemodynamic and haemostatic parameters in COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005